4-D software helps adjust for breathing when treating lung cancer with radiotherapy

April 30, 2010

A new 4-dimensional software program promises to improve the treatment of lung cancer by allowing doctors to take the movement of breathing into account when administering radiotherapy, researchers announced today at the 2nd European Lung Cancer Conference in Geneva, Switzerland.

Some lung tumors shift their position as patients inhale and exhale. The amount of movement depends on where they are in the lung. For example, lesions in the lower lobes may move up to 4 cm.

This movement poses a challenge for doctors treating the cancer with radiotherapy. If they use too small an irradiation field, the tumor can move so far that it is missed by the treatment. To avoid this, standard radiotherapy uses large radiation fields to take into account the respiratory movements, but in doing so can damage large areas of healthy lung tissue.

A newer approach, called 'breathing-adapted radiotherapy' (BART) allows doctors to reduce the amount of radiation delivered, and improve the chance of hitting the tumor, by timing delivery to a particular moment of the respiratory cycle.

"One of the main problems with BART is how to choose the optimal respiratory phase in which to treat the patient," explains Dr Nicolas Peguret from Hôpitau Universitaires de Genève. "This phase is basically unknown and may be in deep inspiration, in expiration or even in a third respiratory phase somewhere between. It may vary from one patient to another because of the variation in tumor localization and in movements of the tumor and of other nearby organs."

Dr Peguret and colleagues have developed software which allows doctors to determine a moment during the respiratory cycle with an optimal tumor position for radiotherapy. "By applying this software together with BART, it may be possible not only to reduce the radiation fields but also to adapt the radiation volume taking into account the varying positions of the tumor and the organs at risk."

The technique involves two steps: first, for each patient, a 4-dimensional computed tomography (4D CT) scan is performed, recording a set of CT slices for each of 10 respiratory phases. This technique is already well known in the medical world, particularly in the field of cardiology.

Second, the new software helps the radiation oncologist to determine if there is a respiratory phase that is most convenient for radiotherapy, based on criteria that have been established by a panel of oncologists.

"The software doesn't require any special equipment and doesn't cause any additional cost," Dr Peguret said. "However, it is important to have a 4D CT available to be able to acquire synchronized image sets, as well as a system that allows synchronization of the thoracic movements during radiotherapy."

"The software will never replace the radiation oncologist," he added. "It simply provides the doctor with information about the movement of the tumor. Depending on the oncologist's clinical objectives, he or she will choose the optimal phase for radiotherapy in an individual patient. In this way, our software transforms the information provided by 4D CT into a real benefit for the patient."

At the conference, Dr Peguret will report that the system may help to increase the dose to the target. "Local control and overall survival depend on the radiation dose that can be delivered to the tumor with a relative sparing of the organs at risk," he said.

"To our knowledge, there is no other similar software on the market. 4D CT and the techniques of BART are still underutilized in oncology. This work might allow its dispersion to other centers with the ultimate aim of improving the survival of the patients."

A Phase II clinical trial is currently underway and results are expected early in 2011.
-end-


European Society for Medical Oncology

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.